Optimization of L-arginine and thiotriazoline compound analysis by high-performance liquid chromatography method
DOI:
https://doi.org/10.14739/2310-1210.2018.6.146760Keywords:
L-arginine, thiotriazoline, HPLC, cardiovascular diseases, ischemiaAbstract
Cardiovascular diseases are the leading cause of death and disability in most countries of the world. Therefore, the crucial task of pharmacy and medicine is the creation of drugs for the treatment of these pathologies. As a result of pharmacological studies, the optimal ratio of L-arginine with thiotriazoline – 4:1 was found. It was proposed to use modern, high-precision method of high-performance liquid chromatography (HPLC) to determine the active substances in the dosage form.
Objective. The purpose of our study is to develop a method for the simultaneous determination of L-arginine and thiotriazoline standardization in model mixture by high-performance liquid chromatography, in particular the selection of the mobile and stationary phase.
Materials and methods. L-arginine (manufactured by Sigma-Aldrich, China), thiotriazoline (manufactured by the State Enterprise Chemical Reagents Plant of the Scientific and Technological Complex Institute of Single Crystals of the National Academy of Sciences of Ukraine) was used for the study. The studies were carried out using a modular BISCHOFF HPLC system (BISCHOFF Analysentechnik GmbH, Germany) with a Lambda 1010 spectrophotometric detector.
Results: At first, the determination was carried out on the reverse phase, with L-arginine practically not retained (coming out at the “dead volume”), and the use of cyanated phase did not significantly affect the retention of L-arginine.
Further, the retention time of L-arginine increased slightly under ion-pair chromatography on the reversed phase, in determining and using the eluent with tetrabutylammonium. The most acceptable result was obtained by using an ion buffer reagent acid buffer – 0.05 % solution of trifluoroacetic acid.
Conclusion. Thus, according to the obtained results, we believe that the use of an acid buffer – 0.05 % solution of trifluoroacetic acid is one of the promising ways for the simultaneous determination of L-arginine with thiotriazoline in the model mixture along with the ion-pair reagent. In the future, we are going to use this technique for the standardization of a combined drug which includes L-arginine and thiotriazoline, in solid and liquid dosage forms.
References
Mazur, I. A., Chekman, I. S., & Belenichev, I. F. (2007). Metabolitotropnye preparaty [Metabolithotropic Drugs]. Zaporozhye. [in Russian].
Mazur, I. A., Voloshin, N. A., Chekman, I. S., Zimenkovskij, B. S., & Stec, V. R. (2005). Tiotriazolin: farmakologicheskie aspektu i klinicheskoe primenenie [Thiotriazoline: pharmacological aspects and clinical usage]. Novosti medicyny i farmacii, 160. [in Russian].
Mazur, I. A., Chekman, I. S., Belenichev, I. F., & Kucherenko, L. I. (2011). Razrabotka lekarstvennukh sredstv na osnove fiksirovannukh kombinacij s antioksidantami – perspektivnoe napravlenie sovremennoj farmakologii [The development of medicines based on fixed combinations with antioxidants is a promising area of modern pharmacology]. Farmakolohiia ta likarska toksykolohiia, 5, 199–200. [in Russian].
Mazur, І. A., Kucherenko, L. I., Belenichev, I. F., Khromylova, O. V. , Siusiuka, V. H. (patentee) (2016) Patent na vynakhid 110597 Ukraina, MPK (2015.01) A61K 31/198 (2006.01), A61K 9/00. Kombinovanyi likarskyi zasib hepatoprotektornoi, kardioprotektornoi, platsentoprotektyvnoi, tokolitychnoi i NO-mimetychnoi dii [Patent 110597, Ukraine, IPC; (2015.01) A61K 31/198 (2006.01), A61K 9/00. Combination Drug with Hepatoprotective, Cardioprotective, Placentoprotective, Tocolytic and NO-Mimetic Action]. Biuleten, 1. [in Ukrainian].
Kucherenko, L., Belenichev, I., Mazur, I., & Khromylova, O. (2017). Methabolithotropic aspects of cardioprotective action of new combined medicine based on L-Arginine and Thiotriazolin at modeling of myocardial infarction. Asian J Pharm Clin Res, 10(10), 158–161.
Pakhomov, V. P. (2003). Khromatohrafiia u khimiko-farmatsevtychnykh doslidzhenniakh [Chromatography in chemical and pharmaceutical studies]. Khimicheskij farmatsevticheskij zhurnal, 37(8), 55–56. [in Ukrainian].
Oiestad, E. L., Johansen, U., & Christophersen, A. S. (2007). Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. Clin Chem, 53, 300–309. doi: 10.1373/clinchem.2006.074237.
Sadek, P. (2009). Rastvoriteli dlya VE'ZHKH [Solvents for HPLC]. Moscow: Binom. Laboratoriya znanij. [in Russian].
Saprykin, L. V. (2006). Praktika i metodicheskie osnovy vysokoe'fektivnoj zhydkostnoj khromatografii [Practical and methodological foundations of high-performance liquid chromatography]. Krasnodar. [in Russian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)